Jetrea Approval History

• FDA approved: Yes (First approved October 17th, 2012)
• Brand name: Jetrea
• Generic name: ocriplasmin
• Company: ThromboGenics NV
• Treatment for: Vitreomacular Adhesion

Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

FDA Approval History for Jetrea

Date	Article
Oct 18, 2012	FDA Approves Jetrea for Symptomatic Vitreomacular Adhesion in the Eyes
Jul 27, 2012	FDA Advisory Committee Recommends ThromboGenics' Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
Jul  3, 2012	ThromboGenics Announces FDA Accepts Filing and Grants Priority Review to Its Biologics License Application for Ocriplasmin Intravitreal Injection
Jun  7, 2012	ThromboGenics Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin
Dec 27, 2011	ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA

See also...

Jetrea (ocriplasmin) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.